POS1308 SINGLE CENTER REAL-LIFE PRACTICE OF BIOLOGICAL THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH JUVENILE ONSET

Background In recent years the use of Biologics (B) at management systemic lupus erythematosus including with juvenile onset (jSLE) has increased. Belimumab (BEL) became first approved B for SLE. The rituximab (RTM), despite status “of label”, remains relevant in a number patients (pts) poor response to standard therapy and presence life-threatening conditions. However, real clinical practice increase slowly, part, due uncertainty over which pts should be treated what stage disease, safety. Objectives To analyze retrospective study efficacy safety jSLE. Methods included all jSLE our pediatric rheumatologic department, who received B. Results Among 160 jSLE, 52 (32.5%) B: 43 – RTM, 12 BEL, 1 abatacept (ABA). 4 2B sequence (2 RTM-BEL; - BEL-RTM; RTM-ABA). proportion was 47% among those RTM center. median age 12.2 y.o. [IQR 9.9; 14.6], disease duration start 2.5 0.9; 4.5]. girls boys ratio = 6.2:1. activity by SLEDAI 16 [12; 22]. 58% underwent more than one course maximum 6 courses. time between each 182 [96–315] days. effective 40 (93%) achievement inactive reduction GC-therapy. Various adverse events (AE) were observed 46.5% as recurrent uncomplicated upper respiratory tract infections being most common (23.2%). discontinued 9 pts: flare Ro-associated vasculitis, inefficiency, 7 serious AEs. Serious AEs included: pneumonia (2.3%), infusion reaction toxic epidermolysis MAS 2 (4.6%), death (inefficiency treatment SLE) (4.6%). receiving BEL 12.7 10.0; 15.0], 1.5 1.0; 2.1]. 1.4:1. 10 [9; 14]. receive year registrated 3 (25%): neutropenia (III degree) 1, SAEs (toxic after 1st infusion, SLE months therapy, discontinuation both pts). One patient, boy, onset, ABA (RTM discontinue MAS). Disease 7.5 years, 10. Treatment allowed decrease (now SLEDAI=2). Now boy receives during 51 good safety, continues GC 5 mg per day, hydroxychloroquine 100 MMF 750 day. Conclusion Our shown that is an acceptable profile if possible reactions are carefully monitored. severe organ lesions, improve long-term prognosis, appointment early can discussed. overall picture emerges optimism advances will realised through targeted increasing different Disclosure Interests None declared